Cовременная тактика лечения больных с ишемической болезнью сердца: принцип дополнительности в терапии и новые представления о ее роли и компонентах
https://doi.org/10.15829/1560-4071-2019-11-112-121
Аннотация
В статье рассматриваются современные представления о роли механической реваскуляризации миокарда и лекарственной противоишемической терапии в лечении больных со стабильным течением ишемической болезни сердца (ИБС). Приводятся современные данные о сравнительной эффективности противоишемических препаратов, которые стали основанием для разработки концепции “бриллиантового подхода” к лечению больных со стабильным течением ИБС, которая предлагается вместо стандартной тактики с использованием иерархического подхода к выбору противоишемических средств. Рассматриваются особенности применения противоишемических препаратов в определенных клинических ситуациях, у больных с наиболее распространенными сопутствующими заболеваниями или осложнениями ИБС, а также при вариантах ИБС, в развитии которых играют роль специфические патофизиологические звенья.
Об авторах
С. Р. Гиляревский
Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия
Россия
Гиляревский Сергей Руджерович — доктор медицинских наук, профессор кафедры клинической фармакологии и терапии.
Москва.
М. В. Голшмид
Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия
Россия
Кандидат медицинских наук, доцент кафедры клинической фармакологии и терапии.
Москва.
И. М. Кузьмина
НИИ скорой помощи им. Н.В. Склифосовского, Москва
Россия
Россия
Кандидат медицинских наук, руководитель отделения неотложной кардиологии.
Москва.
Список литературы
1. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16.
2. Bech GJ, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103:2928-34.
3. Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-24.
4. Pijls NHJ, van Son JA, Kirkeeide RL, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood f low by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation. 1993;87:1354-67.
5. De Bruyne B, Pijls NHJ, Paulus WJ, et al. Transstenotic coronary pressure gradient measurement in humans: in vitro and in vivo evaluation of a new pressure monitoring angioplasty guide wire. J Am Coll Cardiol. 1993;22:119-26.
6. De Bruyne B, Baudhuin T, Melin JA, et al. Coronary flow reserve calculated from pressure measurements in humans: validation with positron emission tomography. Circulation 1994;89:1013-22.
7. Pijls NHJ, de Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary artery stenoses. N Engl J Med. 1996;334:1703-8.
8. Hamilos M, Muller O, Cuisset T, et al. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation. 2009;120:1505-12.
9. Muller O, Mangiacapra F, Ntalianis A, et al. Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. JACC Cardiovasc Interv. 2011;4:1175-82.
10. Puymirat E, Peace A, Mangiacapra F, et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. Circ Cardiovasc Interv. 2012;5:62-8.
11. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional Flow ReserveGuided PCI versus Medical Therapy in Stable Coronary Disease. N Engl J Med. 2012;367:991-1001.
12. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31-40.
13. Chaitman BR, Mori Brooks M, Fox K, Lüscher TF. ORBITA revisited: what it really means and what it does not? Eur Heart J. 2018;39:963-5. doi:10.1093/eurheartj/ehx796.
14. Al-Lamee R, Howard JP, Shun-Shin MJ, et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease. Circulation. 2018;138:1780-92. doi:10.1161/CIRCULATIONAHA.118.033801.
15. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. [Accessed in 2018 March 4]. Available at https://www.ischemiatrial.org/.
16. Lauder Brunton T. On the use of nitrite of amyl in angina pectoris. Lancet. 1867;90:97-8.
17. Murrell W. Nitroglycerine as a remedy for angina pectoris. Lancet. 1879;113;225-7.
18. Srivastava SC, Dewar HA, Newell DJ. Double-blind trial of propranolol (Inderal) in angina of effort. Br Med J. 1964;2:724-5.
19. Melville KI, Shister HE, Huq S. Iproveratril: experimental data on coronary dilatation and antiarrhythmic action. Can Med Assoc J. 1964;90:761-70.
20. Fleckenstein A. History of calcium antagonists. Circ Res. 1983;52:13-6.
21. Goldberg LPI. En studie over sorbiddinitratets karleffekt. (A study of the vascular effect of sorbide dinitrate). Nordisc Med. 1946;29:190-3.
22. Berlin R. Historical aspects of nitrate therapy. Drugs. 1987;33(Suppl 4):1-4.
23. Mehrotra TN, Bassadone ET. Trimetazidine in the treatment of angina pectoris. Br J Oin Pract. 1967;21:553-4.
24. Sakai K, Shiraki Y, Nabata H. Cardiovascular effects of a new coronary vasodilator N-(2-hydroxyethyl)nicotinamide nitrate (SG-75): comparison with nitroglycerin and diltiazem.) Cardiovasc Pharmacol. 1981;3:139-50.
25. Vilaine JP. The discovery of the selective l(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res. 2006;53:424-34.
26. Jain D, Dasgupta P, Hughes LO, et al. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischemic myocardium. Eur J an Pharmacol. 1990;38:111-4.
27. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013:34:2949-3003.
28. Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40:190-4. doi:10.1093/eurheartj/ehy504.
29. van der Does R, Eberhardt R, Derr I, Ehmer B. Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina. J Cardiovasc Pharmacol. 1992;19:S122-S127.
30. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J. 1993;14:30-4.
31. Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment in stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1995;25:1516-21.
32. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. J Clin Pharmacol. 1994;37:279-88.
33. Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96-103.
34. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol. 1997;52:95-100.
35. The SWAN study group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol. 1999;2:213-7.
36. Pehrsson SK, Ringqvist I, Ekdahl S, et al. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol. 2000;23:763-70.
37. Koylan N, Bilge AK, Adalet K, et al. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiol. 2004;59:644-50.
38. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J.2005;26:2529-36.
39. Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393-405.
40. Zhu WL, Shan YD, Guo JX, et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J. 2007;71:826-33.
41. Li Y, Jing L, Li Y, et al. The efficacy and safety of ivabradine hydrochloride versus atenolol in Chinese patients with chronic stable angina pectoris. Pharmacoepidemiol Drug Saf. 2014;23:1183-91.
42. Ferrari R, Camici PG, Crea F, et al. Expert consensus document: A ‘diamond’ approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15:120-32. doi:10.1038/nrcardio.2017.131.
43. Pavasini R, Camici PG, Crea F, et al. Anti-anginal drugs: Systematic review and clinical implications. Int J Cardiol. 2019;283:55-63. doi:10.1016/j.ijcard.2018.12.008.
44. Tardif JC, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540-8. doi:10.1093/eurheartj/ehn571.
45. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091-9. doi:10.1056/NEJMoa1406430
46. Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388:2142-52. doi:10.1016/S0140-6736(16)31326-5.
47. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127:939-53. doi:10.1016/j.amjmed.2014.05.032.
48. Bangalore S, Steg G, Deedwania P, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-9. doi:10.1001/jama.2012.12559.
49. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart fail-ure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):847-9.
50. Borer JS, Swedberg K, Komajda M, et al. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. Cardiology. 2017;136:138-44. doi:10.1159/000449243.
51. Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97:278-86. doi:10.1136/hrt.2010.208751.
52. Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100:1506-10. doi:10.1136/heartjnl-2014-305482.
53. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-52.
54. Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol. 2015;8:1048-56. doi:10.1161/CIRCEP.115.002856.
55. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118(12):1250-8. doi:10.1161/CIRCULATIONAHA.108.778019.
56. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42-8.
57. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201-7.
58. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469-91.
59. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med. 2012;12:26. doi:10.1186/1471-2466-12-26.
60. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-87. doi:10.1001/archinternmed.2010.112.61.
61. George CF. Beta-receptor blocking agents. Prescribers J. 1974;14:93-8.
62. Joint Formulary Committee. British National Formulary Vol. 65 (Pharmaceutical Press, 2013).
63. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;CD005508. doi:10.1002/14651858.CD005508.pub3.
64. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906-18. doi:10.1016/S0140-6736(16)00278-6.
65. Masani ND, Northridge DB, Hall RJ. Severe coronary vasospasm associated with hyperthyroidism causing myocardial infarction. Br Heart J. 1995;74:700-1.
66. Abbate A, Hamza M, Cassano AD, et al. Sympathectomy as a treatment for refractory coronary artery spasm. Int J Cardiol. 2012;161:e7-9. doi:10.1016/j.ijcard.2012.03.006.
67. Cattaneo M, Porretta AP, Gallino A. Ranolazine: Drug overview and possible role in primary microvascular angina management. Int J Cardiol. 2015;181:376-81. doi:10.1016/j.ijcard.2014.12.055.
68. Tagliamonte E, Rigo F, Cirillo T, et al. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease. Echocardiography. 2015;32:516-21. doi:10.1111/echo.12674.
69. Bairey Merz CN, Handberg EM, Shufelt CL, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016;37:1504-13. doi:10.1093/eurheartj/ehv647.
70. van der Hoeven NW, van Royen N. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease, another funny aspect of the funny channel? Heart. 2014;100:98-9. doi:10.1136/heartjnl-2013-305045.
71. Tagliamonte E, Cirillo T, Rigo F, et al. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate. Adv Ther. 2015;32:757-67. doi:10.1007/s12325-015-0237-x.
72. Nalbantgil S, Altintig A, Hasan Y, et al. The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol. 1999;8:40-3. doi:10.1007/BF01616842.
73. Leonova IA, Boldueva S, Zakharova O, Gaykovaya L. Trimetazidine improves symptoms and reduces microvascular dysfunction in patients with microvascular angina. Eur Heart J. 2017;38:ehx501. P887. doi:10.1093/eurheartj/ehx501.P887.
Рецензия
Для цитирования:
Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Cовременная тактика лечения больных с ишемической болезнью сердца: принцип дополнительности в терапии и новые представления о ее роли и компонентах. Российский кардиологический журнал. 2019;(11):112-121. https://doi.org/10.15829/1560-4071-2019-11-112-121
For citation:
Gilyarevskiy S.R., Golshmid M.V., Kuzmina I.M. Modern strategy of treating patients with coronary artery disease: complementarity principle in therapy and new ideas about its role and components. Russian Journal of Cardiology. 2019;(11):112-121. (In Russ.) https://doi.org/10.15829/1560-4071-2019-11-112-121
Просмотров:
1140
Послать статью по эл. почте 